Inter-individual Variability in the Pre-clinical Drug Cardiotoxic Safety Assessment—Analysis of the Age–Cardiomyocytes Electric Capacitance Dependence by Polak, Sebastian & Fijorek, Kamil
Inter-individual Variability in the Pre-clinical Drug Cardiotoxic
Safety Assessment—Analysis of the Age–Cardiomyocytes
Electric Capacitance Dependence
Sebastian Polak & Kamil Fijorek
Received: 7 December 2011 /Accepted: 29 February 2012 /Published online: 13 March 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Electrical phenomena located within the plasma
membrane of the mammalian cardiac cells are connected
with the cells’ main physiological functions—signals pro-
cessing and contractility. They were extensively studied and
described mathematically in so-called Hodgkin–Huxley par-
adigm. One of the physiological parameters, namely cell
electric capacitance, has not been analyzed in-depth. The
aim of the study was to validate the mechanistic model
describing the capacitive properties of cells, based on a
collected experimental dataset which describes the electric
capacitance of human ventricular myocytes. The gathered
data was further utilized for developing an empirical corre-
lation between a healthy individual’s age and cardiomyocyte
electric capacitance.
Keywords Inter-individual variability.Cardiomyocyte
electriccapacitance.Humancardiomyocyte.Virtual
population
Introduction
Electrical phenomena located within the plasma membrane
of the mammalian cardiac cells are connected with the cell’s
main physiological functions—signals processing and con-
tractility. Both of these elements are well-known from an
anatomical, physiological, and functional point of view even
at the molecular and submolecular level. The first area,
namely electrical activity has been studied and described
in the form of an equation derived by Hodgkin and Huxley
[Eq. 1] which is described as the H-H paradigm [1]. This
paradigm is extensively used as a base for multiple models
describing heart cells’ electric activity [2–4].
Vm ¼
Istim þ Iion
Cm
ð1Þ
where:
Vm Membrane voltage [mV]
Iion Sum of ionic currents [pA/pF]
Istim Stimulation potential [pA]
Cm Cell electric capacitance [pF]
Models based on the Hodgkin and Huxley paradigm are
used in a wide range of areas, from heart diseases and
disorders’ simulation to drug cardiotoxicity assessment [5,
6]. The ionic activity (Iion) is subdivided into separate ionic
currents described with the use of various mathematical
techniques [7, 8]. Being the main triggering points for
arrhythmias (including drug-dependent ones) they were
widely investigated [9–12]. A large amount of time and
effort has been put into studying the ionic activity and to a
lesser degree, the stimulation potential. However, cell electric
capacitance has not been studied as intensely.
The cell membrane, which consists of a double lipid layer
shows a great resistance to the flow of ionic currents. As an
effect of the ion’s separation, the electric potential across the
membrane is formed. Maintaining this status is possible
through the action of the ionic pumps, including the
Na
+/K
+ exchanger. The Na
+/K
+-ATPase for every three
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DOI 10.1007/s12265-012-9357-8sodium ions pumped out from the cell, transports only two
potassium ions into the cell. The electromagnetic field
across the membrane causes the attraction of the charged
particles. Anions from the extracellular fluid are attracted to
the outer side of the membrane. At the same time cations
from cytosol accumulate inside. The consequences of such
phenomena are demonstrated in other biophysical measures
characterizing biological cells, including conductance and
capacitance. Capacitance (Cm) defines the amount of elec-
tric charge that can be stored in a capacitor at a given
voltage. In the biological membranes there are two spaces,
which could be recognized as plates, formed by the cytosol
and extracellular fluid. These are electricity conductors,
separated by an insulator (the phospholipid bilayer). In such
a situation, the membrane behaves electrically as a capaci-
tor. Capacitance measurements can be used to study the
changes in cell surface area. This is because capacitance is
proportional to the cell surface area and therefore depends
on the shape of the cell affecting the area [13]. The equation
describing this relationship is as follows [14]:
Cm ¼ "r   "0  
A
d
ð2Þ
where:
Cm Cell electric capacitance [pF]
A Cell surface area [μm
2]
εr Dielectricconstant of thecellmembrane[dimensionless]
ε0 Electric constant (vacuum permittivity) [F/m]
d Thickness of the membrane [nm]
The model presented above can be treated as a mecha-
nistic representation of the observed phenomenon.
In a recent study described elsewhere, it was hypothe-
sized that the electric capacitance of the cardiac cells
depends on the cell surface area. Furthermore, according
to the study, the cell surface area is subsequently dependent
on the age of the individuals [15]. Realistic parameter values
are needed in order to mimic the inter-individual variability
in the in silico environment and also to simulate cell mem-
brane electric activity. It is especially important when deal-
ing with excitable cells like cardiomyocytes. Their
mathematical expressions have to have support in the phys-
iology. This is a crucial factor for the realistic simulations of
drugs and pathophysiological-condition-dependent altera-
tions. The above-mentioned previously developed and de-
scribed model combines the individuals’ age as an
independent variable and the cardiomyocyte volume and
area as the dependent variables. Based on that correlation,
every member of the randomly built virtual population is
described by a set of parameters including membrane ca-
pacitance calculated with the use of Eq. 2. This equation
expresses a mechanistic model whose performance should
be further verified. Verification can be done by comparing
the results of the simulations with the real values, derived
from human cardiac cells, of the cardiomyocyte electric
capacitance.
Study Aims
The main aim of the study was to verify the predictive
quality of the previously established correlation, combining
healthy individuals’ age and cardiomyocyte volume/area/
electric capacitance, with the use of the collected and ana-
lyzed data describing the electric capacitance of human
ventricular myocytes.
The same data, selected based on a strictly prepared
procedure, was then used to achieve an additional study
aim—a derivation of the novel empirical models, corre-
lating: the healthy individual’s age and cardiomyocyte
electric capacitance and the ages and cardiomyocyte
electric capacitance of individuals suffering from various
heart diseases.
The third aim includes the assessment of the influence of
the above-mentioned approaches on the simulated action
potential duration.
Materials and Methods
Data Collection
In order to collect data describing human cardiomyocyte
electric capacitance values, database searches were per-
formed. The Scopus, Medline, and Google Scholar data-
bases were searched. There was no time limit for the
search query. The key phrases, included in either the article
title, keywords, or abstract, were: ‘cardiomyocyte’, ‘cardio-
myocyte parameters’, ‘cardiomyocyte capacitance’, ‘cardiac
myocyte’, ‘cardiac cell’, ‘ventricular myocyte’, ‘capaci-
tance’, ‘human’, ‘volunteers’, ‘healthy’, and ‘control’. The
reports that were found were scrutinized for additional refer-
ences not covered by the electronic search. Native data was
extracted in various ways, depending on the article structure
and data presentation method. If not stated otherwise, all
data values are presented as algebraic means with the
corresponding standard error of the mean (SE). The collect-
ed data can be subdivided into two groups—patient data and
cell data. The first group covers: sex (male, female), cells’
location (left ventricle, right ventricle; epicardium, endocar-
dium), disease occurrence (healthy, diseased), number of
individuals in the study, average, minimum, and maximum
age. The latter group includes: measurement temperature
and number of probes. Information describing age is pre-
sented in years [years] and electric capacitance is described
in picofarads [pF].
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The collected data was further divided according to the
above described parameters. The crucial factor is health
status, as the previously established age–cardiomyocyte
volume/area–electric capacitance correlation was developed
based on healthy individuals’ data. Considering this, it was
assumed that the performance verification of the model
would be done with the use of identically pre-processed
data (healthy individuals only), although a full set of
collected data is presented.
The data used during the new empirical models develop-
ment was carefully analyzed. Inclusion criteria were as
follows: clearly defined health status (either health or dis-
ease), information regarding average age, and electric ca-
pacitance. There are some contradictory reports, although
according to the majority of the previously published
papers, it was assumed that the sex, cell location, and
measurement temperature do not significantly influence
the electric capacitance [16, 17]. Two studies describing
age-capacitance correlation were based on the biological
material derived from young individuals [18, 19]. Both of
them describe non-healthy children diagnosed with the te-
tralogy of Fallot, which is connected with right ventricular
hypertrophy [20, 21]. As we were not able to find separate
reports describing healthy young individuals, they were
intentionally included in the healthy population. This being
due to the fact that this was the only available information.
Non-healthy individuals were characterized by various
diseases, but the common feature was heart insufficiency.
This can furthermore be connected with heart cells' hyper-
trophy. According to that they were separately analyzed
with the use of similar techniques, and the results were
compared with those derived from healthy individuals. For
the modeling stage, only individuals with an evidently de-
fined health status were included to assure model consisten-
cy. No disease-specific analysis was performed, as the data
amount for various diseases was not sufficient and the
clinical condition was not always clearly defined in the
available sources.
Calculations
All simulations were done either with the use of previously
published models and tools or models derived as a part of
this study. The tool which enables the generation of virtual
populations, with the use of various approaches, was imple-
mented as an easy-to-use Excel file. This is freely available
and can be found in the supplementary materials attached to
the current article. All simulations were run in ten replica-
tions. These were based on the number of individuals in-
volved in the different studies and also on the characteristics
regarding the age and gender of the individuals. Such a
procedure was introduced to avoid randomization bias.
The parameters describing the ages of the groups of indi-
viduals (mean, SD), which were derived directly from the
analyzed studies, were then used to fully mimic the de-
scribed populations. The Weibull model was chosen as the
default for the description of the age distribution in a healthy
population [22].
Results Comparison
Various statistics were used to assess the prediction accuracy
of the model described by Eq. 1. The fold error was calcu-
lated as is presented in Eq. 3:
fold error ¼
 observed
predicted
no
if observed > predicted
predicted
observed
  
if predicted > observed
ð3Þ
Additionally, the percentage of simulation results’ fold
errors, which fell below an absolute value of 2, was
presented.
The bias of the prediction model was assessed with the
use of the geometric mean fold error measure (MFE). This is
presented in Eq. 4. Such a measure was chosen due to its
characteristics. These allow for the equal weighting of the
under and over estimates. A mean fold error ≤2 is generally
considered successful, indicating that most of the predicted
values fall within the twofold range of the observed ones
(between 0.5 and 2.0) [23, 24].
MFE ¼ 10
Pn
i¼1
jlog predicted
observed ðÞ j
npredictions ð4Þ
The root mean squared error (RMSE), as presented in
Eq. 5, was used to assess the accuracy of the predictions.
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ Pn
1 observed   predicted ðÞ
2
n
s
ð5Þ
Statistical Modeling
It was assumed that the cardiomyocyte capacitance (Cm)
distributionhasnon-negativesupport(capacitancecannottake
negative values). It was also assumed that the capacitance
distribution is skewed to the right. The most popular distribu-
tion showing this kind of behavior is log-normal which was
tested as a default model with the assumption that the natural
logarithm of the capacitance can be modeled as a normal
random variable with a constant variance and age-dependent
mean (log-linear model) as presented in Eq. 6:
log Cm ðÞ ¼ b0 þ b1   age þ "; "   N 0;σ ðÞ ð 6Þ
The second tested model was a double-log-linear regres-
sion model. The model assumes that the natural logarithm of
J. of Cardiovasc. Trans. Res. (2012) 5:321–332 323the capacitance can be modeled as a normal random
variable. This normal random variable has a constant
variance and mean that depends on the natural loga-
rithm of the age (Eq. 7):
log Cm ðÞ ¼ b0 þ b1   log age ðÞ þ "; "   N 0;σ ðÞ ð 7Þ
Both models parameters were estimated using ordinary
least squares. The lm function, available in the R system for
statistical computing, was used [25].
Simulation Study
The simulation studies were done with the use of the
tenTusscher model of the human left ventricle myocyte
[4]. The transmembrane potential was chosen as an
investigated endpoint. M cell variation (midmyocar-
dium) was used. Two parameters were modified to
apply for physiological changes—the volume of cardi-
omyocyte (Vc) and electric capacitance (Cm). Volume
of the cardiomyocytes was simulated with the previously
published tool [15].
Moxifloxacin, the most commonly used positive con-
trol in thorough QTc (TQTc) studies, was chosen as a
model drug to simulate the electric capacitance influ-
ence on the drug-triggered APD modification [26]. The
in vitro data, describing the concentration-dependent
ionic currents inhibition, was gathered from the avail-
able literature. For the hERG-transfected HEK cells, at a
physiological temperature and potassium ions’ concen-
tration similar to the physiological (4 mM) environment
which mimics human cardiomyocytes, the reported IC50
value was 35.7 μM[ 27]. Two different, reported as the
maximal in the healthy volunteers clinical trials concen-
trations, were tested—M105.57 μMa n dM 2 011.21 μM
[26, 28]. Assuming that the concentration–inhibition
relation is described by the Hill equation (n01), the
predicted IKr potassium current inhibition was calculated as
being 13% and 24%, respectively.
In all cases, the simulation time was set to 500 ms.
Software
R environment was used for the statistical computing.
ToxComp system was used to simulate human ventricular
cardiomyocyte action potential [29].
Results
Table 1 presents the full set of data collected during the
literature review process. Information is grouped according
to the health status. There were 24 studies found combining
age and the cardiac myocyte electric capacitance in humans.
Among them nine studies fulfilled the inclusion criteria for
healthy individuals and were included at the model building
stage (Table 2). One study done with the use of biological
material derived from the healthy individuals was removed
during the analysis as there was no age clearly defined [30].
Mechanistic Model Validation—Results for Healthy
Individuals
The cumulative results of the simulations (sim) are
presented in Fig. 1. The results were created with the
use of the model described by Eq. 2, in combination
with the age–cardiomyocyte volume/area model and
then compared with the observed data. The graph
presents the average values derived from ten indepen-
dent simulations linked with the corresponding observed
values for all studies separately. Detailed results with
error measures are presented in Tables 3 and 4.
The detailed results of simulations mimicking single
studies are presented separately and attached as supplementary
materials.
Empirical Models Derivation—Results for Healthy
and Diseased Individuals
Empirical representation of the direct correlation between
age and human left ventricle cardiomyocyte electric capac-
itance was based on the log-linear and double-log-linear
models. The estimates of the model’s parameters are pre-
sented below [Tables 5 and 6].
Both the estimate of the intercept and the slope are
significant (p value<0.05). It can be inferred that a 1-year
increase in age is associated, on average, with an increase of
about 0.0115 and 0.022 in log cardiomyocyte capacitance
for healthy and diseased individuals, respectively. The re-
sidual standard error (the variation of the individual points
about the regression line) is 0.3323 and 0.3642. For the
models representing healthy and heart-diseased individuals’
the results were R
200.4 and 0.56. This means that 40% and
56% of the variability observed in log cardiomyocyte ca-
pacitance can be explained by the estimated regression
equation for both populations.
Both the estimate of the intercept and the slope are
significant (p value<0.05). It can be inferred that a 1-year
increase in log-age is associated, on average, with an in-
crease of about 0.2522 and 0.3702 in log cardiomyocyte
capacitance for healthy and diseased individuals, respectively.
The residual standard error (the variation of individual
points about the regression line) is 0.3116 and 0.3582.
R
200.47 and 0.58, or 47% and 58% of the variability
observed in log cardiomyocyte capacitance can be
e x p l a i n e db yt h ee s t i m a t e dr e g r e s s i o ne q u a t i o nf o rb o t h
populations.
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cardiomyocyte capacitance and age, along with a regression
curve and 95% pointwise prediction bands for the log-linear
model. It is worth noticing that the prediction intervals
are asymmetric (right skewed), and they do not allow
for negative values.
The plot below [Fig. 3] shows the relationship between
cardiomyocyte capacitance and age along with a regression
curve and 95% pointwise predictionbands for the double-log-
linear model.
Simulation Study Results—Cardiotoxicity Assessment
A simulation study was performed to examine the influence
of the demographic (age) and physiological parameters.
These were parameters were the cardiomyocyte volume
Table 2 Dataset selected for the modeling step (healthy individuals)—after applying the inclusion/exclusion criteria
Source Patient-dependent data Cell-dependent data
Location/health status Number
(all)
Number
male
Number
(female)
Average
age [years]
SE
[years]
Age min
[years]
Age max
[years]
Average
Cm [pF]
SE
[pF]
Temp
[°C]
No.
[41] Ventricle Left Healthy 13 11 2 39.5 13.6 194 21.7 37 28
[42] Ventricle Left Healthy 7 3 4 41.55 5.7 210 37
[43] Ventricle Left Healthy 5 5 0 57.8 5.8 49 67 96 1.0 33
[16] Ventricle Epi Left Healthy 6 41.6 16 51 184.5 20.5 22 12
Ventricle Endo Left Healthy 6 41.6 16 51 174.2 16.9 22 22
[45] Ventricle Left Healthy 15 7 8 44.3 4.3 182 15.0 37 19
[38] Ventricle Epi Left Healthy 4 3 1 75 2.5 70 80 227.4 14.9 16
Ventricle Endo Left Healthy 4 3 1 75 2.5 70 80 153.8 17.5 5
[40] Ventricle Left Healthy 16 9 7 42.4 7.3 29 49 126.2 13.4 25
[44] Ventricle Right Healthy 3 46 7.5 31 54 179 15.0 36
[36] Ventricle Healthy 7 5 2 66 3 355 23 37 11
[18] Ventricle Right Disease
a 7 2.92 1 1.33 7.58 92.6 8.17 36 41
[19] Ventricle Right Disease
a 9 2.6 0.77 1.33 7.58 80.4 5.92 36 62
aIntentionally included in the final dataset; please see Materials and methods for further explanation
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Fig. 1 Experimental and
simulated (sim) human
cardiomyocytes electric
capacitance as a function
of age
326 J. of Cardiovasc. Trans. Res. (2012) 5:321–332Table 3 Dataset selected for the modeling step (heart disease individuals)—after applying the inclusion/exclusion criteria
Source Patient-dependent data Cell-dependent data
Location/health status Number
(all)
Number
(male)
Number
(female)
Average
age [years]
SE
[years]
Age min
[years]
Age max
[years]
Cm
[pF]
SE
[pF]
Temp
[°C]
No.
[35] Ventricle Left Epi Disease 12 9 3 52 5.0 17 63 285.0 17.0 37 39
[16] Ventricle Left Disease 22 41.4 3.5 163.3 7.6 22 73
[18] Ventricle Right Disease 7 2.92 1.0 1.33 7.58 92.6 8.2 36 41
[36] Ventricle Disease 11 9 2 49 4.0 584.0 56.0 37 22
[19] Ventricle Right Disease 9 2.6 0.77 1.33 7.58 80.4 5.9 36 62
[37] Ventricle Left Disease 11 8 3 55.55 3.8 21 67 196.0 14.0 37 31
[17] Ventricle Left Disease 5 5 0 40.4 7.4 17 54 269.0 31.0 36 14
Ventricle Left Disease 5 0 5 47.8 4.8 39 60 292.0 37.0 36 15
[38] Ventricle Left Epi Disease 10 8 2 50.7 4.1 17 63 292.0 22.1 28
Ventricle Left Endo Disease 10 8 2 50.7 4.1 17 63 225.4 27.9 16
[39] Ventricle Left Disease 4 50 5.0 260.0 63.0 36 8
Ventricle Left Disease 6 57 2.0 239.0 46.0 36 12
[40] Ventricle Left Disease 8 5 3 46.4 8.8 34 61 133.8 14.7 20
Table 4 Simulation results obtained with the use of Eq. 2 in combination with the age–cardiomyocyte volume/area model compared with the
observed data
Study Individual Cardiomyocyte Error
Age [years] SE [years] Cm [pF] SE [pF] Fold error (% ≤2 fold) MFE RMSE
[41] av sim data 41.48 4.47 103.52 22.72 −1.99 (70) 1.93 93.2
exp data 39.50 13.60 194.00 21.70
[42] av sim data 44.76 3.96 100.20 20.87 −2.17 (50) 2.13 111.2
exp data 41.55 5.70 210.00
[43] av sim data 57.64 2.00 149.26 18.38 1.55 (100) 1.55 55.14
exp data 57.80 5.80 96.00 1.00
[44] av sim data 45.13 2.17 110.41 14.12 −1.64 (100) 1.63 69.39
exp data 46.00 7.51 179.00 15.00
[16] epi av sim data 39.25 2.57 81.41 13.36 −2.35 (20) 2.31 104.54
exp data 41.60 184.50 20.50
[16] endo av sim data 40.43 2.84 83.31 12.88 −2.12 (30) 2.10 91.31
exp data 41.60 174.20 16.90
[36] av sim data 64.73 2.61 205.13 28.22 −1.76 (80) 1.74 152.05
exp data 66.00 3.00 355.00 23.00
[45] av sim data 43.25 3.32 101.87 18.50 −1.84 (70) 1.81 81.85
exp data 44.30 4.30 182.00 15.00
[38] epi av sim data 75.10 1.22 295.86 37.93 1.10 (100) 1.29 81.39
exp data 75.00 2.50 227.40 14.90
[38] endo av sim data 75.35 1.04 331.53 43.89 2.16 (40) 2.12 188.26
exp data 75.00 2.50 153.80 17.50
[40] av sim data 38.33 1.46 66.83 5.97 −1.89 (70) 1.89 59.49
exp data 42.40 7.30 126.20 13.40
[18] av sim data 3.44 0.51 18.54 2.11 −5.08 (0) 5.04 74.11
exp data 2.92 1.00 92.60 8.17
[19] av sim data 3.27 0.55 18.10 2.28 −4.50 (0) 4.47 62.33
exp data 2.60 0.77 80.40 5.92
J. of Cardiovasc. Trans. Res. (2012) 5:321–332 327and the capacitance on the cardiac myocyte transmembrane
potential. The remaining parameters were assumed to be
constant and had default values (i.e., sarcoplasmic reticulum
volume). The APD90 (action potential at 90% of repolari-
zation) was chosen as a measure.
Tables 7 and 8 show the relationship between cardiomyo-
cyte volume [μm
3], electric capacitance [pF], and APD90
for the two tested models.
Discussion
As presented in Eq. 2, the mechanistic model describes the
phenomenon responsible for the electric charge storage at
the phospholipid border. This border is lying between intra-
and extracellular environments. Membrane capacitor effi-
ciency is proportional to the cell surface area and therefore
depends on the shape of the cell affecting the area, as well as
the membrane thickness. Assuming that the membrane
thickness and the dielectric constant of the cell membrane
have constant values, then the cell area becomes a pivotal
parameter regulating electric capacitance. The combination
of the above-mentioned model with empirical correlation
combining age and cardiomyocyte area into one semi-
mechanistic system can be effe c t i v e l yu s e di np r a c t i c e
[15]. Such an approach has some practical advantages giv-
ing the opportunity to have a look inside the process; al-
though its accuracy has to be validated. To perform the
validation process, experimental data describing the electric
capacitance of human cardiomyocytes was collected. To
Table 5 Point and covariate matrix estimates of the log-linear model
combining age and cardiomyocyte electric capacitance for the healthy
and diseased population
Population Parameter Point
estimate
Covariance matrix estimate (×1,000)
β0 β1
Healthy β0 4.5686 44.4077 −0.8102
β1 0.0115 −0.8102 0.0183
σ 0.3323
Disease β0 4.4306 70.1864 −1.4269
β1 0.022 −1.4269 0.0339
σ 0.3642
Table 6 Point and covariate matrix estimates of the double-log-linear
model combining age and cardiomyocyte electric capacitance for the
healthy and diseased population
Population Parameter Point
estimate
Covariance matrix estimate (×1,000)
β0 β1
Healthy β0 4.2040 85.9116 −22.5930
β1 0.2522 −22.5930 6.5074
σ 0.3116
Disease β0 4.0782 117.8562 −31.3204
β1 0.3702 −31.3204 9.0843
σ 0.3582
Fig. 2 Relationship between cardiomyocyte capacitance and age
along with a regression curve and 95% point-wise prediction bands
for the log-linear models—comparison between healthy individuals
(blue line and blue squares) and heart-diseased individuals (red line
and red squares)
Fig. 3 Relationship between cardiomyocyte capacitance and age
along with a regression curve and 95% point-wise prediction bands
for the double-log-linear models—comparison between healthy indi-
viduals (blue line and blue squares) and heart-diseased individuals (red
line and red squares)
328 J. of Cardiovasc. Trans. Res. (2012) 5:321–332simulate the described populations, a previously developed
virtual population generator was used. The parameters de-
scribing the age distribution, namely the mean value and the
standard deviation of the mean, were utilized. For seven,
from the 11 simulated studies, the fold difference between
the observed and predicted data fell below 2. This is gener-
ally recognized as the acceptance level. As the studies were
simulated in ten replicates, additional accuracy measure was
expressed as a percentage number of virtual studies with a
fold error below 2. Eight, from the 11 studies, have a
minimum of 50% of the simulations which fulfilled such
requirements. Such results allow for the making of a state-
ment regarding the high accuracy of the tested tool. It is
worth noticing that all the described observations are valid
for the populations of healthy individuals which were taken
for analysis after applying strict including/excluding criteria.
During drug virtual clinical trials, further practical use of the
described and validated system should be limited to healthy
volunteers. At the same time, it can be clearly seen that the
mechanistic model does not differentiate between cells from
various locations. Such results may be an indirect indication
that such differentiation could be justified.
In nine, from the 11, studies mechanistic model, tested in
current study, under predicted the cardiomyocyte electric
capacitance. It suggests bias, which can be an effect of the
previously mentioned assumption, namely the cylindrical
shape of the ventricular cardiac myocytes. Membrane inva-
ginations (transverse tubules) increase the total area of the
cell when comparing with a cylinder, and thus increase the
electric capacitance. Assuming that ca. 30% of the mem-
brane is present in the t-tubules, a proportional increase in
the capacitance can be expected [31], which is supported by
the current study’s findings.
A separate leg of the study was focused on the develop-
ment of an empirical model which directly correlates age
and human cardiomyocyte electric capacitance. Separate
models describing healthy volunteers and individuals suf-
fering from heart diseases were developed. In both cases,
based on the observations, it was assumed that the capaci-
tance distribution is skewed to the right and has non-
negative support. It was also assumed that log-normal and
double-log-normal distribution were chosen as the default
models.
The double-log-linear model has been presented for
information’s sake, as it fits the observed data better than
the other tested models; although the log-linear model seems
to be more physiological and is recommended by the
authors. Due to the model structure, electric capacitance
equals to zero (Cm00) is assumed for age zero (newborns).
This has no support in the physiology.
The main limitation of the proposed models, describing
healthy individuals result from the assumptions made at the
data analysis stage. The lack of available information in the
literature regarding the electric capacitance in non-adults,
created the necessity to include data from young non-
healthy individuals. The simulation study results show that
there was up to a fivefold under prediction, when using the
mechanistic model for young individuals. It clearly points
Table 7 Relationship between cardiomyocyte volume, electric capacitance, and APD90 for the log-linear model
Age [years]
15 20 25 30 35 40 45 50 55 60 65 70 75
Cm [pF] 129.8 142.2 135.8 147.0 171.3 178.4 167.5 177.6 200.8 193.0 224.3 245.5 224.5
Volume [μm
3] 3,119 4,499 5,477 6,826 7,987 10,345 13,539 16,383 19,132 22,938 31,540 42,975 47,841
APD90 no drug 286 284 285 285 286 288 289 290 291 292 293 295 296
APD90 M1 333 336 338 340 340 343 346 348 348 351 353 357 358
APD90 M2 340 343 345 347 347 349 353 354 355 357 360 363 365
Table 8 Relationship between cardiomyocyte volume, electric capacitance, and APD90 for the double-log-linear model
Age [years]
15 20 25 30 35 40 45 50 55 60 65 70 75
Cm [pF] 113.1 145.4 147.4 174.4 166.2 183.4 180.7 189.8 174.6 188.2 185.8 215.1 212.6
Volume [μm
3] 3,119 4,499 5,477 6,826 7,987 10,345 13,539 16,383 19,132 22,938 31,540 42,975 47,841
APD90 no drug 283.6 284.4 284.4 285.2 286.0 287.9 288.9 289.8 290.8 291.7 293.6 295.5 295.5
APD90 M1 333 336 338 338 341 343 346 347 349 351 354 357 359
APD90 M2 341 342 344 345 347 349 352 354 356 358 361 364 365
J. of Cardiovasc. Trans. Res. (2012) 5:321–332 329out the likely bias of the subsequently developed empirical
model. Information describing electric capacitance derived
from the young, unaltered, ventricular myocytes would be
necessary on order to improve the model’sp r e d i c t i v e
quality.
Separate models, describing the age and cardiomyocytes
electric capacitance for the population with heart diseases,
were developed. In all cases, the data was derived from
patients suffering from various heart diseases. Regardless
of the type of pathology, most of the conditions affecting the
heart are connected with cardiac cell hypertrophy. Even
when considering the loss of the transverse tubules observed
in such conditions, it was expected that heart cell hypertro-
phy could significantly influence the electric capacitive
capabilities of the myocyte, and thus the whole electric
behavior. As the elderly population, highly affected by heart
disorders, is strongly exposed to drugs, the possibility to
virtually test the chemical’s influence on the heart action
with the use of reliable data and models is highly beneficial.
The developed models can be considered as being com-
plementary to the previously developed mechanistic model.
The latter one is a part of the computational system for the
drug cardiotoxicity assessment, based on the mathematical
model for human ventricular cardiomyocyte [4]. Both the
empirical and mechanistic models represent two
approaches, described as top–down and bottom–up, respec-
tively. Both of them have their advantages and disadvan-
tages. As presented in the current study, the direct
correlation between age and cell electric capacitance fits
better to the experimental data. Therefore, this offers better
interpolation capabilities. This is obvious, considering
that the same data was used during their development.
A tt h es a m et i m et h e yd on o to f f e rd i r e c ti n s i g h ti n t o
the mechanism lying behind the described phenomena,
which is a major advantage of the mechanistic model.
The expected increase in the cardiomyocyte area and the
following electric capacitance, after implementing a dif-
ferent volume calculation method, can improve the
mechanistic model’s predictability. Taking the above-
mentioned arguments into account, the authors suggest
that the mechanistic model (part of the ToxComp system)
should be utilized.
The simulations results presented in Tables 7 and 8 prove
that the combination of the physiological parameters (in this
case—the cardiomyocyte volume to electric capacitance
ratio) ought to be analyzed rather than just single variables.
The larger the above-mentioned ratio the higher the APD90
value and the total action potential duration. The combina-
tion of such a high-risk element with a concomitantly given
drug or drug combination can result in a health risk increase
(arrhythmia). It demonstrates the need for an inter-
individual variability assessment during the pre-clinical,
in-silico-based, drug safety studies.
The latter one, namely the in silico drugs toxicity assess-
ment, offers direct clinical translation of the proposed mod-
el. The previously mentioned ToxComp system offers an in
silico realized platform for the in vitro–in vivo extrapolation
of the cardiotoxic effect with an inter-individual variability
analysis. The pharmaceutical industry is viably interested in
early cardiac safety assessment, the mechanism of which
lies in the acquired long QT syndrome. The wide clinical
evidence regarding drug-triggered heart rate disruption has
resulted in compulsory cardiac risk assessment during the
drug development process. This is strictly required by drug
agencies and described in the available guidelines [32, 33].
The best known model of the general population, which is
the final target of any drug which is under development, is a
cohort included in a specific clinical trial (TQTc study—
thorough QTc study) where the heart rate corrected change
of the QT interval length is the final point. There are,
although, some limitations of different natures—meritorious
(the clinical trial is still a model!) and most importantly,
financial. The latter one is essential at the early stage of drug
development. For such reasons surrogates are recommen-
ded. They include in vivo animal studies (ventricular repo-
larization disruption assessment) and the in vitro evaluation
of the drug effects on the ionic current. This is done through
a native or heterologously expressed IKr channel protein,
such as those encoded by hERG. In both cases an essential
question arises—what is the translation between in vitro/
animal in vivo results and the human situation? In that
regard, the in vitro–in vivo extrapolation approach, with
the use of the mathematical models and simulated virtual
population, may be a useful solution. Such methods
were successfully applied in the pharmacokinetic drug
characterization [34].
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